EA201291116A1 - Способ получения метансульфонатных солей ралфинамида или их r-энантиомеров - Google Patents

Способ получения метансульфонатных солей ралфинамида или их r-энантиомеров

Info

Publication number
EA201291116A1
EA201291116A1 EA201291116A EA201291116A EA201291116A1 EA 201291116 A1 EA201291116 A1 EA 201291116A1 EA 201291116 A EA201291116 A EA 201291116A EA 201291116 A EA201291116 A EA 201291116A EA 201291116 A1 EA201291116 A1 EA 201291116A1
Authority
EA
Eurasian Patent Office
Prior art keywords
water
salt
modification
acetone
carbon atoms
Prior art date
Application number
EA201291116A
Other languages
English (en)
Other versions
EA021389B1 (ru
Inventor
Клаудио Джордано
Эрвин Вальдвогель
Original Assignee
Ньюрон Фармасьютикалс С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньюрон Фармасьютикалс С.П.А. filed Critical Ньюрон Фармасьютикалс С.П.А.
Publication of EA201291116A1 publication Critical patent/EA201291116A1/ru
Publication of EA021389B1 publication Critical patent/EA021389B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к новому способу получения и/или очистки соли соединения (S)-2-[4-(2-фторбензилокси)бензиламино]пропанамида, то есть ралфинамида, или соответственного R-энантиомера, и метансульфокислоты с высокими выходами и очень высокими энантиомерной и химической степенями чистоты в форме кристаллической безводной полиморфной модификации, идентифицируемой как форма А, где упомянутая соль является в значительной мере свободной от примесей, имеющих генотоксический эффект, таких как (C-C)алканилметансульфонаты, и от остаточных растворителей, известных как их потенциальные вещества-предшественники, таких как (C-C)алканолы или сложные эфиры алканолов и низших алкановых кислот. Способ предусматривает (i) получение и/или кристаллизацию соли из воды, ацетона, алифатического кетона с 4-5 атомами углерода или из их смеси с водой, или (ii) суспендирование твердой соли (а) с водой, (b) со смесью воды с ацетоном или с алифатическим кетоном с 4-5 атомами углерода, (с) с ацетоном, алифатическим кетоном с 4-5 атомами углерода или с их смесью, или (iii) воздействие на твердую соль потока воздуха, имеющего высокую степень относительной влажности, и в том случае, когда полученный продукт состоит полностью или частично из кристаллов с кристаллической полугидратной псевдополиморфной модификацией формы Н, превращение упомянутого продукта в кристаллы безводной формы А путем проведения процесса удаления воды. Кристаллическая полугидратная псевдополиморфная модификация формы Н метансульфоната ралфинамида или его R-энантиомера является полезным промежуточным соединением для получения кристаллической безводной полиморфной модификации формы А, свободной от
EA201291116A 2010-04-27 2011-04-06 Способ получения метансульфонатных солей ралфинамида или их r-энантиомеров EA021389B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161207 2010-04-27
PCT/EP2011/055309 WO2011134763A1 (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers

Publications (2)

Publication Number Publication Date
EA201291116A1 true EA201291116A1 (ru) 2013-04-30
EA021389B1 EA021389B1 (ru) 2015-06-30

Family

ID=42634917

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291116A EA021389B1 (ru) 2010-04-27 2011-04-06 Способ получения метансульфонатных солей ралфинамида или их r-энантиомеров

Country Status (28)

Country Link
US (2) US9505708B2 (ru)
EP (1) EP2563355B1 (ru)
JP (3) JP5808392B2 (ru)
KR (1) KR101851118B1 (ru)
CN (2) CN102858330B (ru)
AR (1) AR085171A1 (ru)
AU (1) AU2011246707B2 (ru)
BR (1) BR112012027623B1 (ru)
CA (1) CA2794389C (ru)
CY (1) CY1117879T1 (ru)
DK (1) DK2563355T3 (ru)
EA (1) EA021389B1 (ru)
ES (1) ES2590128T3 (ru)
HK (2) HK1179881A1 (ru)
HR (1) HRP20161077T1 (ru)
HU (1) HUE030504T2 (ru)
IL (1) IL222532A (ru)
LT (1) LT2563355T (ru)
ME (1) ME02509B (ru)
MX (1) MX342697B (ru)
NZ (2) NZ602648A (ru)
PL (1) PL2563355T3 (ru)
PT (1) PT2563355T (ru)
RS (1) RS55084B1 (ru)
SI (1) SI2563355T1 (ru)
SM (1) SMT201600266B (ru)
TW (1) TWI492919B (ru)
WO (1) WO2011134763A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011246707B2 (en) * 2010-04-27 2014-11-20 Newron Pharmaceuticals S.P.A. Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers
CN103804341B (zh) * 2012-11-13 2018-04-10 中国人民解放军军事医学科学院毒物药物研究所 酰胺衍生物及其医药用途
CN104761531B (zh) * 2014-01-03 2017-12-01 中国人民解放军军事医学科学院毒物药物研究所 镇痛活性化合物及其医药用途
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
CN115368310A (zh) * 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
EP1423168B1 (en) 2001-09-03 2006-02-08 Newron Pharmaceuticals S.p.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
CA2514574A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
DK1658062T3 (da) 2003-08-25 2010-05-31 Newron Pharm Spa Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
ES2347581T3 (es) * 2004-09-10 2010-11-02 Newron Pharmaceuticals S.P.A. Uso de (r)-(halobenciloxi)bencilamino-propanamidas como moduladores selectivos del canal de sodio y/o calcio.
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
DK2474521T3 (en) 2006-06-19 2016-10-31 Newron Pharm Spa High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus
JP5315674B2 (ja) * 2007-11-19 2013-10-16 セントラル硝子株式会社 非水電池用電解液及びこれを用いた非水電池
CA2936209C (en) * 2007-12-11 2020-02-11 Newron Pharmaceuticals S.P.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
EA019529B1 (ru) 2007-12-19 2014-04-30 Ньюрон Фармасьютикалс С.П.А. Альфа-аминоамидные производные, применяемые в лечении психиатрических расстройств
WO2009109334A1 (en) 2008-03-07 2009-09-11 Newron Pharmaceuticals S.P.A. (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
AU2011246707B2 (en) * 2010-04-27 2014-11-20 Newron Pharmaceuticals S.P.A. Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers

Also Published As

Publication number Publication date
CA2794389C (en) 2016-08-23
US9505708B2 (en) 2016-11-29
JP2013528577A (ja) 2013-07-11
EA021389B1 (ru) 2015-06-30
CN105037188B (zh) 2017-06-23
RS55084B1 (sr) 2016-12-30
CA2794389A1 (en) 2011-11-03
JP2017197553A (ja) 2017-11-02
BR112012027623B1 (pt) 2021-07-06
HK1213872A1 (zh) 2016-07-15
US20170029365A1 (en) 2017-02-02
ME02509B (me) 2017-02-20
NZ602648A (en) 2014-10-31
CN102858330B (zh) 2015-07-22
HUE030504T2 (en) 2017-05-29
CN102858330A (zh) 2013-01-02
ES2590128T3 (es) 2016-11-18
WO2011134763A1 (en) 2011-11-03
JP5808392B2 (ja) 2015-11-10
DK2563355T3 (en) 2016-09-12
CN105037188A (zh) 2015-11-11
JP6345154B2 (ja) 2018-06-20
SMT201600266B (it) 2016-08-31
US9856207B2 (en) 2018-01-02
MX2012012093A (es) 2012-12-17
EP2563355B1 (en) 2016-06-08
SI2563355T1 (sl) 2016-10-28
CY1117879T1 (el) 2017-05-17
IL222532A (en) 2017-09-28
AR085171A1 (es) 2013-09-18
IL222532A0 (en) 2012-12-31
US20130039983A1 (en) 2013-02-14
AU2011246707B2 (en) 2014-11-20
TW201139344A (en) 2011-11-16
EP2563355A1 (en) 2013-03-06
KR20130094212A (ko) 2013-08-23
TWI492919B (zh) 2015-07-21
MX342697B (es) 2016-10-10
KR101851118B1 (ko) 2018-04-23
JP6450420B2 (ja) 2019-01-09
HK1179881A1 (en) 2013-10-11
NZ700221A (en) 2016-04-29
LT2563355T (lt) 2016-09-26
PT2563355T (pt) 2016-09-02
BR112012027623A2 (pt) 2016-08-09
HRP20161077T1 (hr) 2016-10-21
PL2563355T3 (pl) 2016-12-30
JP2015180664A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
CY1117879T1 (el) Διεργασια για την παραγωγη μεθανοσουλφονικων αλατων ραλφιναμιδης ή των r-εναντιομερων αυτων
MX2013011257A (es) Proceso para la preparacion de dronedarona por n-butilacion.
AR059916A1 (es) Procesos y productos intermedios para preparar compuestos esterico
RU2627698C2 (ru) Натриевая соль (2s, 5r)-6-бензилокси-7-оксо-1,6-диаза-бицикло[3.2.1]октан-2-карбоновой кислоты и ее получение
WO2010045900A1 (en) A method for the preparation of dabigatran and its intermediates
IN2014CN03482A (ru)
JP2008540496A (ja) ２‐アミノ‐６‐プロピルアミノ‐４，５，６，７‐テトラヒドロベンゾチアゾールおよび中間化合物の分割方法
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
EA201201666A1 (ru) Промежуточные соединения агомелатина и способ их получения
JP2013528577A5 (ru)
JP2004511477A (ja) Ｒ（＋）α−リポ酸の合成
ITMI20120311A1 (it) Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato
ES2686929T3 (es) Procedimiento de resolución óptica para compuesto bicíclico utilizando catalizador asimétrico
RU2015147242A (ru) Способ получения арформотерола или его соли
JP6640220B2 (ja) プラジカンテルの製造方法
DE602006008335D1 (de) Neuartiges verfahren zur herstellung von quaternärer säure und ammoniumsalzen
EA201490464A1 (ru) Соль и полиморф пиразолопиримидинонового соединения и фармацевтическая композиция, содержащая их, их способ получения и применение
EA202190170A1 (ru) Способ получения ингибитора бромодомена
WO2012070896A3 (en) Synthetic method of enantiomerically pure 2,2'-dihydroxy-1,1'-binaphthyl-3-carboxylic acid
MA34464B1 (fr) Procede pour la preparation de formes enantiomeres de derives d'acide 2,3- diaminopropionique
BR112014029361A2 (pt) método de produção de ácido tereftálico e seus derivados
WO2010086700A3 (en) An improved process for the preparation of choline salt of fenofibric acid and its novel polymorph
MX356686B (es) Procesos e intermediarios para la preparación de un inhibidor macrocíclico de la proteasa del virus de la hepatitis c.
EP3292102B1 (en) Isoindolinones, processes for the production of chiral derivatives thereof and use thereof